Human serum albumin and p53-activating peptide fusion protein is able to promote apoptosis and deliver fatty acid-modified molecules

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Joshi, Michelle R ^a   Yao, Nianhuan ^a   Myers, Kenneth A ^b   Li, Zhiyu ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; FLUORESCEIN ISOTHIOCYANATE; HUMAN SERUM ALBUMIN P53 ACTIVATING PEPTIDE FUSION PROTEIN; HYBRID PROTEIN; LONG CHAIN FATTY ACID; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; UNCLASSIFIED DRUG; FATTY ACID; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PEPTIDE; SERUM ALBUMIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FATTY ACID TRANSPORT; FEASIBILITY STUDY; INTERNALIZATION; OSTEOSARCOMA CELL; BIOLOGICAL MODEL; DRUG EFFECTS; ENDOCYTOSIS; ENZYME ACTIVATION; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

APOPTOSIS; BIOLOGICAL TRANSPORT; CASPASES; CELL LINE, TUMOR; ENDOCYTOSIS; ENZYME ACTIVATION; FATTY ACIDS; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PEPTIDES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896716673     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080926     Document Type: Article

References (43)

1. Zhang XX, Eden HS, Chen X (2012) Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release 159: 2-13. doi:10.1016/j.jconrel.2011.10.023. PubMed: 22056916.
2. Hupp TR, Meek DW, Midgley CA, Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71: 875-886. doi: 10.1016/0092-8674(92)90562- Q. PubMed: 1423635.
3. el-Deiry WS (1998) Regulation of p53 downstream genes. Semin Cancer Biol 8: 345-357. doi:10.1006/scbi.1998.0097. PubMed: 10101800.
4. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665. doi:10.1038/nature05541. PubMed: 17251932. (Pubitemid 46232887)
5. Rinn JL, Huarte M. (2011) To repress or not to repress: this is the guardian's question. Trends Cell Biol 21: 344-353. doi:10.1016/j.tcb.2011.04. 002. PubMed: 21601459.
6. Bond GL, Hu W, Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3-8. doi: 10.2174/1568009053332627. PubMed: 15720184. (Pubitemid 40321795)
7. Freedman DA, Wu L, Levine AJ (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55: 96-107. doi:10.1007/s000180050273. PubMed: 10065155. (Pubitemid 29077858)
8. Böttger A, Böttger V, Garcia-Echeverria C, Chène P, Hochkeppel HK et al. (1997) Molecular characterization of the hdm2-p53 interaction. J Mol Biol 269: 744-756. doi:10.1006/jmbi.1997.1078. PubMed: 9223638. (Pubitemid 27280843)
9. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV et al. (2005) Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7: 547-559. doi:10.1016/j.ccr.2005.04.029. PubMed: 15950904. (Pubitemid 40799248)
10. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848. doi:10.1126/science.1092472. PubMed: 14704432. (Pubitemid 38174664)
11. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J (2006) MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 281: 33030-33035. doi:10.1074/jbc.C600147200. PubMed: 16905541. (Pubitemid 46036685)
12. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM (2006) Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 281: 33036-33044. doi:10.1074/jbc.M605405200. PubMed: 16905769. (Pubitemid 46036686)
13. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873. doi:10.1038/nrc2763. PubMed: 19935675.
14. Li C, Pazgier M, Yuan W, Liu M, Wei G et al. (2010) Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. J Mol Biol 398: 200-213. doi:10.1016/j.jmb.2010.03.005. PubMed: 20226197.
15. Pazgier M, Liu M, Zou G, Yuan W, Li C et al. (2009) Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A 106: 4665-4670. doi:10.1073/pnas.0900947106. PubMed: 19255450.
16. Fasano M, Curry S, Terreno E, Galliano M, Fanali G et al. (2005) The extraordinary ligand binding properties of human serum albumin. IUBMB Life 57: 787-796. doi:10.1080/15216540500404093. PubMed: 16393781. (Pubitemid 43062399)
17. Chuang VT, Kragh-Hansen U, Otagiri M (2002) Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 19: 569-577. doi:10.1023/A:1015396825274. PubMed: 12069157. (Pubitemid 34553662)
18. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132: 171-183. doi: 10.1016/j.jconrel.2008.05.010. PubMed: 18582981.
19. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N et al. (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794-7803. doi:10.1200/JCO.2005.04.937. PubMed: 16172456. (Pubitemid 46657376)
20. Vousden KH, Prives C (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413-431. doi:10.1016/j.cell.2009.04.037. PubMed: 19410540.
21. Boratyński J, Opolski A, Wietrzyk J, Górski A, Radzikowski C (2000) Cytotoxic and antitumor effect of fibrinogen-methotrexate conjugate. Cancer Lett 148: 189-195. doi:10.1016/S0304-3835(99)00334-1. PubMed: 10695996. (Pubitemid 30047107)
22. Tzefos M, Olin JL Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann Pharmacother 44: 1294-1300. doi:10.1345/aph.1P047. PubMed: 20530705.
23. Peterson GE (2006) Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin 22: 2613-2619. doi:10.1185/030079906X154178. PubMed: 17166343.
24. Rustgi VK (2009) Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin 25: 991-1002. doi:10.1185/03007990902779186. PubMed: 19275518.
25. Pignatello R, Guccione S, Forte S, Di Giacomo C, Sorrenti V et al. (2004) Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling. Bioorg Med Chem 12: 2951-2964. doi: 10.1016/j.bmc.2004.03.040. PubMed: 15142554. (Pubitemid 38622129)
26. Singh Y, Palombo M, Sinko PJ (2008) Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 15: 1802-1826. doi:10.2174/ 092986708785132997. PubMed: 18691040.
27. Kratz F, Müller IA, Ryppa C, Warnecke A (2008) Prodrug strategies in anticancer chemotherapy. Chemmedchem 3: 20-53. doi:10.1002/cmdc.200700159. PubMed: 17963208.
28. Cregg JM, Tolstorukov I, Kusari A, Sunga J, Madden K et al. (2009) Expression in the yeast Pichia pastoris. Methods Enzymol 463: 169-189. doi:10.1016/S0076-6879(09)63013-5. PubMed: 19892173.
29. Travis J, Bowen J, Tewksbury D, Johnson D, Pannell R (1976) Isolation of albumin from whole human plasma and fractionation of albumin-depleted plasma. Biochem J 157: 301-306. PubMed: 962868.
30. Chen RF (1967) Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem 242: 173-181. PubMed: 6016603.
31. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953. doi:10.1126/science.274.5289.948. PubMed: 8875929. (Pubitemid 26398409)
32. Schon O, Friedler A, Bycroft M, Freund SM, Fersht AR (2002) Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 323: 491-501. doi:10.1016/S0022-2836(02)00852-5. PubMed: 12381304. (Pubitemid 35283675)
33. El-Deiry WS (2003) The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22: 7486-7495. doi:10.1038/sj.onc.1206949. PubMed: 14576853.
34. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G et al. (2000) p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 14: 2358-2365. doi:10.1101/gad.827300. PubMed: 10995391.
35. Tao W, Levine AJ (1999) P19(ARF) stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A 96: 6937-6941. doi:10.1073/pnas.96.12.6937. PubMed: 10359817. (Pubitemid 29274988)
36. Kuo ML, Duncavage EJ, Mathew R, den Besten W, Pei D et al. (2003) Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 63: 1046-1053. PubMed: 12615721. (Pubitemid 36278437)
37. Barak Y, Juven T, Haffner R, Oren M (1993) Mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468. PubMed: 8440237. (Pubitemid 23073692)
38. Spector AA (1975) Fatty acid binding to plasma albumin. J Lipid Res 16: 165-179. PubMed: 236351.
39. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD (2003) Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 284: L187-L196. PubMed: 12471015. (Pubitemid 35471272)
40. Desai N, Trieu V, Yao Z, Louie L, Ci S, et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12: 1317-1324 (Pubitemid 43342524)
41. Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A et al. (2012) Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun 3: 610. doi:10.1038/ncomms1607. PubMed: 22215085.
42. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM et al. (2003) Mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23: 462-472. doi: 10.1128/MCB.23.2.462-473.2003. PubMed: 12509446.
43. Caelles C, Helmberg A, Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53 target genes. Nature 370: 220-223. doi:10.1038/370220a0. PubMed: 8028670. (Pubitemid 24236778)